Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Valuing the company by Earnings History

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Valuing the company by Earnings History

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Valuing the company by Earnings History

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is expected to announce second quarter financial results after market close (confirmed) on August 02, 2017. The company added about -5.4% percent in value since last earnings when it was at $14.85. Based on the most relevant historical data, there is a N/A percent probability for share price to go down following the next earnings report. Looking further into earnings reaction history, the stock had moved down 14 times out of last 27 quarters. It has topped earnings-per-share estimates 41% of the time in its last 12 earnings reports. It missed earnings on 4 occasions, and it has met expectations 0 time.

Vanda Pharmaceuticals Inc. (VNDA) History

Overall, the average earnings surprise was -60.04 percent over the past four quarters. Back on May 02, 2017, it posted earnings per share at $-0.17 which topped the consensus $-0.19 projection (Negative surprise of -12.37%). Revenue came in at $37.42M versus consensus estimate of $38.28M. The stock gained 0.67% percent the day following the earnings was released, and on 7th day price change was -3.70% percent.

On February 15, 2017, it posted earnings per share at $-0.01 versus the consensus estimate of $-0.09 (Negative surprise of -89.19%). Revenue of $38.24M was below the $38.39M analysts had expected. The stock dropped the day following the earnings was released, and on 7th day price change was .

On November 02, 2016, it posted earnings per share at $-0.01, topped the consensus estimate of $-0.08 (Negative surprise of -87.50%). Revenue for the quarter was $38.48M while analysts had expected revenues to come in at $37.9M. The stock fell -4.88% the day following the earnings was released, and on 7th day price change was 5.93%.

On July 27, 2016, it posted earnings per share at $-0.11 compared with the consensus estimate of $-0.22 (Negative surprise of -51.11%). That came on revenues of $36.03M for the quarter. Analysts had expected $35.78M in revenue.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Expectations

In front of Q3 earnings release, Wall Street is expecting earnings per share of $-0.28. The analysts’ current consensus range is $-0.49-$-0.14 for EPS. The market consensus range for revenue is $39.5M-$42.2M, with an average of $40.47M.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) last closed at $15.20, sending the company’s market cap around $677.16M. The consensus 12-month price target from brokerage firms covering the stock is $21.33. The share price has declined -15.56% from its best level in 52 weeks and advanced -4.70% this year. It recently traded in a range of $-$ at a volume of 1,024,058 shares. The stock ended last trading session with the price nearly 9.35% higher for the last 5 trading days, rebounding 45.87% from its 52-week low.